J&J gets EU OK for TB drug; Gilead recalls 3 Atripla lots; GSK tops list of new drug approvals;

@FiercePharma: And the best-read special report, our newest: The top 10 pharma companies by 2013 revenue. Report | Follow @FiercePharma

@TracyStaton: ICYMI: It's trial by fire for Zogenix, as painkiller Zohydro's launch meets public furor. News | Follow @TracyStaton

@EricPFierce: Novartis has more skin in the dermatology game with EU approval of Xolair to treat chronic hives. Story | Follow @EricPFierce

@CarlyHFierce: Working on a new report... looks like it's time to add "write extensive Advair pieces off the top of my head" to my list of party tricks. | Follow @CarlyHFierce

> Johnson & Johnson ($JNJ) has gotten conditional approval from the European Commission for its drug Sirturo bedaquiline to treat pulmonary multi-drug resistant tuberculosis (MDR-TB) in adults, an indication that the FDA granted in December 2012. Story

> Gilead Sciences ($GILD) has recalled three lots of its HIV drug Atripla after some vials manufactured by a contractor in China were found to have red rubber particles in them. Story

> India wants the U.S. to lower the awards in whistleblower cases, saying that drug company employees will alter records themselves in an effort to bring a lawsuit. Story

> The FDA has ordered a label change for Johnson & Johnson ($JNJ) antibacterial drug Doribax, sometimes used by doctors to treat patients who develop pneumonia while on ventilators, to say it is not approved for treating any type of pneumonia because of its high risk of death. Announcement

> A Missouri Senate committee proposed legislation that would require students living on college campuses to get vaccinated against bacterial meningitis. Story

Medical Device News

@FierceMedDev: Quotient, a UK diagnostics outfit, filed plans for a $75M IPO. Via Renaissance Capital. Brief | Follow @FierceMedDev

@MarkHFierce: The European Patent Office tossed out an Edwards heart valve patent--a big victory for rival Medtronic. More | Follow @MarkHFierce

@MichaelGFierce: Study: In two-drug, HIV-preventing vaginal ring, only one drug does the job. Piece | Follow @MichaelGFierce

@EmilyWFierce: Stapler-sized device could identify disease biomarkers and insulin levels, all in one read. Story via RTT News | Follow @EmilyWFierce

@GalenMoore: Last year's M&A darling, Biomet files for an IPO. It's said to be looking for a $1B raise. News | Follow @GalenMoore

> AngioDynamics plans late FY14 rollout for latest dialysis catheter. Story

> Vermillion reports Q4 earnings fueled by its ovarian cancer diagnostic. Article

Biotech News

@FierceBiotech: After 2 years trailing Boston, San Francisco rules our list of the top 15 cities for biotech VC. Report | Follow @FierceBiotech

@JohnCFierce: And continuing to run strong from Wednesday, which is unusual--FDA rejects Eli Lilly's SGLT2 diabetes drug empagliflozin. Story | Follow @JohnCFierce

@DamianFierce: NewLink's cancer vaccine brings hopeful investors back down to earth. More | Follow @DamianFierce

@EmilyMFierce: Stem cell therapy developed by International Stem Cell Corp. improves Parkinsons symptoms in monkeys. Story | Follow @EmilyMFierce

> GlaxoSmithKline's FDA batting average tops the industry; Lilly, not so much. Article

> A Phase III win puts Incyte's cancer drug in line for blockbuster status. Piece

And Finally... A study by EvaluatePharma says that GlaxoSmithKline ($GSK) has had 20 new molecular entities (NMEs) approved by the FDA between 2008 and 2013 and that they should generate about $12 billion in sales by 2018 for the U.K. drugmaker. Story